QUOTE AND NEWS
StreetInsider.com  May 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/TranS1%2C+Inc.+%28TSON%29+Misses+Q1+EPS+by+5c%3B+Guides+Q2+Sales/7415603.html for the full story.
Globe Newswire  May 2  Comment 
WILMINGTON, N.C., May 2, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the
Globe Newswire  Apr 25  Comment 
WILMINGTON, N.C., April 25, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release first quarter 2012 financial and operating results after market close on Tuesday, May 8, 2012. Ken Reali, President and Chief
Globe Newswire  Apr 5  Comment 
WILMINGTON, N.C., April 5, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing spine products to treat degenerative conditions of the spine affecting the lower lumbar region,
Globe Newswire  Mar 23  Comment 
NEW ORLEANS, March 22, 2012 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until March 26, 2012 to file lead plaintiff
StreetInsider.com  Mar 5  Comment 
Keryx Biopharma (Nasdaq: KERX) 26% HIGHER; breaking out following a late article from Seeking Alpha on Friday. The piece is entitled "FDA Approval Practically A Done Deal For Keryx And ZEterna Zentaris". TranS1 Inc. (Nasdaq: TSON) 25% HIGHER;...
Benzinga  Mar 5  Comment 
StreetInsider.com  Mar 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TranS1+%28TSON%29+Gets+Approval+from+AMA+CPT+for+AxiaLIF+Implant+in+L5-S1+Spinal+Fusion/7238296.html for the full story.
Globe Newswire  Mar 2  Comment 
NEW YORK, March 2, 2012 (GLOBE NEWSWIRE) -- Shareholders of TranS1 Inc. ("TranS1" or the "Company") (Nasdaq:TSON) are reminded of the securities class action lawsuit filed against the Company and certain of its officers. The class action
StreetInsider.com  Feb 27  Comment 
UPGRADES Goldman Sachs lifts Ariba (Nasdaq: ARBA) from Neutral to Conviction Buy, its price target moves from $34 to $40. Click Here for more color. Canaccord Genuity upgrades TranS1 Inc (Nasdaq: TSON) from Hold to Buy, its price target raised...
Globe Newswire  Feb 24  Comment 
WILMINGTON, N.C., Feb. 24, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing minimally invasive spine products to treat degenerative conditions of the spine affecting the lower





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki